By Chemistry World2008-11-27T08:55:00
In a bid to strengthen its position in the race to develop new hepatitis therapies, UK pharma giant GlaxoSmithKline (GSK) has agreed to buy Genelabs Technologies in a deal worth $57 million (£35 million).